A Phase 2 interventional study of Cetuximab and Cisplatin in Head and Neck Cancer, sponsored by Eli Lilly and Company. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing cetuximab in Head and Neck Neoplasms — 2 open to participants now, 7 under way, 2 of them phase 3. Cetuximab · Head and Neck Neoplasms.
Among the 86 studies testing cetuximab in Head and Neck Neoplasms, this one is the 6th largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2010, is one of 52 in phase 2, and was the 47th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →2 of the 86 studies testing cetuximab in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 6 · Phase 4 2
First in 1999; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 37 across the 84 interventional studies. Of the 72 that completed or were terminated, 39 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 86 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
14 studies in Head and Neck Neoplasms by Eli Lilly and Company: 1 open now, 3 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 14 studies in Head and Neck Neoplasms by Eli Lilly and Company, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2010, is one of 7 in phase 2, and was the 7th registered.
Eli Lilly and Company’s Head and Neck Neoplasms studies by the year they started, since 2005.
2 of the studies testing cetuximab in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04722523Memorial Sloan Kettering Cancer CenterA Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | 2027-06-20 |
| NCT06869473Gruppo Oncologico del Nord-OvestCetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. | 2027-08-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing cetuximab in Head and Neck Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 14 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus 5-fluorouracil (5-FU)] administered every 3 weeks. After 18 weeks, participants who benefit from this treatment may continue to receive cetuximab once-weekly until progression of the disease, an unacceptable side effect occurs, participants withdraw consent, or the study is closed.
In the second part of this study, 200 participants will be randomized in 2 arms:
All these 200 participants will receive other chemotherapy drugs (cisplatin or carboplatin plus 5-FU) administered every 3 weeks. After 18 weeks, participants who benefit from this treatment may continue to receive cetuximab once-weekly until progression of the disease, an unacceptable side effect occurs, participants withdraw consent, or the study is closed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1: Week 1 - Cetuximab 400 milligrams per square meter (mg/m\^2) on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met.
Drug: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil
Cycle 1: Week 1 - Cetuximab 400 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met.
Drug: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil
Cycle 1: Week 1 - Cetuximab 400 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met.
Drug: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil
Administered intravenously
Also known as: Erbitux, LY2939777
Administered intravenously
Administered intravenously
Administered intravenously
Also known as: 5-FU
Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013
September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality.
Time frame: Part 2: Baseline to end of combination therapy (up to 18 weeks)
Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013
January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality.
Time frame: Part 2: Baseline to end of combination therapy or date first participant switched to US commercial cetuximab (up to 18 weeks)
Overall Survival (OS)
OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.
Time frame: Parts 1 and 2: Randomization to Date of Death from any Cause (Up to 36.3 Months)
Progression-Free Survival (PFS)
PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.
Time frame: Parts 1 and 2: Randomization to Progression of Disease or Death from any Cause (Up to 32.7 Months)
Percentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version \[v\]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)\*100.
Time frame: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
Number of Participants With Anti-Cetuximab Antibodies
Time frame: Day 1, Week 1 of Cycles 3 and 5 (postbaseline samples were collected prior to infusion).
Percentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR)
Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria.
Time frame: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
Maximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing
The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy.
Time frame: Part 2: Cycle 1, Day 1: 0 hours [(h); immediately postdose], 1 h, 2 h, and 24 h postdose
Cmax of Cetuximab at Steady State
A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m\^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.
Time frame: Part 2: Weekly from Cycle 1, Week 3 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
Area Under the Concentration Curve (AUC) of Cetuximab at Steady State
A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m\^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.
Time frame: Part 2: Weekly from Cycle 1, Day 1 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Milestone | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU |
|---|---|---|---|
| Started | 33 | 81 | 73 |
| Received at least 1 dose of study drug | 33 | 77 | 71 |
| Completed | 33 | 77 | 71 |
| Not completed | 0 | 4 | 2 |
September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality.
| participants | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|
| Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013 | 76 | 68 |
January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality.
| participants | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI), |
|---|---|---|
| Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013 | 75 | 68 |
OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.
| Months | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|---|
| Overall Survival (OS) | 9.13 (6.60 to 10.38) | 9.23 (6.90 to 11.80) | 9.46 (6.87 to 11.43) |
PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.
| Months | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|---|
| Progression-Free Survival (PFS) | 4.57 (3.22 to 5.32) | 4.34 (3.52 to 5.78) | 5.59 (4.04 to 6.28) |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version \[v\]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)\*100.
| percentage of participants | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|---|
| Percentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) | 24.2 (9.6 to 38.9) | 32.5 (22.0 to 42.9) | 36.6 (25.4 to 47.8) |
| participants | All Participants (Cetuximab) |
|---|---|
| Number of Participants With Anti-Cetuximab Antibodies | 4 |
Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria.
| percentage of participants | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|---|
| Percentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR) | 69.7 (54.0 to 85.4) | 58.4 (47.4 to 69.4) | 62.0 (50.7 to 73.3) |
The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy.
| micrograms per milliliter (μg/mL) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|
| Maximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing | 208 ± 10.2 | 208 ± 7.8 |
A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m\^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.
| micrograms per milliliter (μg/mL) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|
| Cmax of Cetuximab at Steady State | 225 ± 17.7 | 199 ± 15.3 |
A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m\^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.
| micrograms*hours/milliliter (μg*h/mL) | Part 2: Combination Therapy: Cetuximab (US Commercial) | Part 2: Combination Therapy: Cetuximab (Manufactured by BI) |
|---|---|---|
| Area Under the Concentration Curve (AUC) of Cetuximab at Steady State | 21900 ± 31.8 | 18800 ± 25.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | — | 20/33 (60.6%) | 32/33 (97%) |
| Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | — | 48/77 (62.3%) | 64/77 (83.1%) |
| Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | — | 42/71 (59.2%) | 62/71 (87.3%) |
| Event | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/33 | 3/77 | 2/71 |
| DehydrationMetabolism and nutrition disorders | 5/33 | 7/77 | 9/71 |
| AnaemiaBlood and lymphatic system disorders | 4/33 | 4/77 | 5/71 |
| NauseaGastrointestinal disorders | 4/33 | 7/77 | 2/71 |
| VomitingGastrointestinal disorders | 4/33 | 7/77 | 4/71 |
| FatigueGeneral disorders | 3/33 | 1/77 | 1/71 |
| PneumoniaInfections and infestations | 3/33 | 5/77 | 5/71 |
| SepsisInfections and infestations | 3/33 | 5/77 | 1/71 |
| NeutropeniaBlood and lymphatic system disorders | 2/33 | 6/77 | 3/71 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/33 | 1/77 | 5/71 |
| Event | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU |
|---|---|---|---|
| NauseaGastrointestinal disorders | 19/33 | 34/77 | 33/71 |
| AnaemiaBlood and lymphatic system disorders | 18/33 | 19/77 | 27/71 |
| HypomagnesaemiaMetabolism and nutrition disorders | 18/33 | 30/77 | 29/71 |
| FatigueGeneral disorders | 16/33 | 35/77 | 37/71 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 17/33 | 26/77 | 19/71 |
| NeutropeniaBlood and lymphatic system disorders | 15/33 | 17/77 | 23/71 |
| DiarrhoeaGastrointestinal disorders | 15/33 | 23/77 | 22/71 |
| VomitingGastrointestinal disorders | 15/33 | 17/77 | 25/71 |
| HypokalaemiaMetabolism and nutrition disorders | 14/33 | 17/77 | 23/71 |
| ConstipationGastrointestinal disorders | 9/33 | 16/77 | 25/71 |
Participants who received at least 1 dose of any study drug (cetuximab, cisplatin, carboplatin, or 5-FU).
| Age, Continuous(years) | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | Total |
|---|---|---|---|---|
| Mean | 62.9 ± 8.74 | 57.1 ± 10.75 | 59.4 ± 10.49 | 59.0 ± 10.47 |
| Sex/Gender, Customized(participants) | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | Total |
|---|---|---|---|---|
| Female | 11 | 9 | 15 | 35 |
| Male | 22 | 68 | 55 | 145 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 16 | 9 | 27 |
| Asian | 0 | 1 | 2 | 3 |
| Black or African American | 2 | 7 | 2 | 11 |
| White | 29 | 53 | 56 | 138 |
| More than 1 race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | Total |
|---|---|---|---|---|
| United States | 27 | 25 | 28 | 80 |
| Mexico | 1 | 23 | 15 | 39 |
| Canada | 5 | 29 | 27 | 61 |
| Disease Stage at Study Entry(participants) | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | Total |
|---|---|---|---|---|
| Locoregional | 6 | 34 | 32 | 72 |
| Metastatic | 27 | 43 | 38 | 108 |
| Unknown or not reported | 0 | 0 | 1 | 1 |
| Karnofsky Performance Status (KPS)(participants) | Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU | Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU | Total |
|---|---|---|---|---|
| KPS 70 | 5 | 9 | 7 | 21 |
| KPS 80 | 19 | 28 | 22 | 69 |
| KPS 90 | 5 | 32 | 31 | 68 |
| KPS 100 | 4 | 8 | 11 | 23 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Jun 2010, a primary completion of Aug 2013 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetuximab · Cisplatin · Carboplatin · Fluorouracil